Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HealthLynked (HLYK) EBITDA (2016 - 2025)

Historic EBITDA for HealthLynked (HLYK) over the last 10 years, with Q3 2025 value amounting to -$716499.0.

  • HealthLynked's EBITDA rose 5640.89% to -$716499.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.0 million, marking a year-over-year increase of 3915.0%. This contributed to the annual value of -$4.6 million for FY2024, which is 1327.52% down from last year.
  • Per HealthLynked's latest filing, its EBITDA stood at -$716499.0 for Q3 2025, which was up 5640.89% from -$655542.0 recorded in Q2 2025.
  • Over the past 5 years, HealthLynked's EBITDA peaked at -$463967.0 during Q3 2021, and registered a low of -$4.1 million during Q4 2022.
  • For the 5-year period, HealthLynked's EBITDA averaged around -$1.3 million, with its median value being -$1.1 million (2024).
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 22359.22% in 2022, then surged by 7377.29% in 2023.
  • Quarter analysis of 5 years shows HealthLynked's EBITDA stood at -$1.8 million in 2021, then tumbled by 124.88% to -$4.1 million in 2022, then soared by 73.77% to -$1.1 million in 2023, then skyrocketed by 33.36% to -$720338.0 in 2024, then grew by 0.53% to -$716499.0 in 2025.
  • Its last three reported values are -$716499.0 in Q3 2025, -$655542.0 for Q2 2025, and -$903341.0 during Q1 2025.